[Epidermal growth factor receptor (EGF) in head-and-neck cancers].
EGFR is frequently overexpressed and is associated with a poor prognosis in head and neck carcinoma (HNC). Among the biological and cellular effects resulting from EGFR targeting, there are the possibilities to restore apoptotic capacities and to reduce DNA-repair activity, to inhibit angiogenesis and tumor cell migration. This suggests the potential interest of the combination between anti-EGFR drugs and cytotoxic agents, especially ionizing radiation with promising results obtained at the clinical level in locally advanced HNC.
Bourhis
J
J
Institut Gustave Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif.
Tao
Y G
YG
Zhang
P
P
Deutsch
E
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D003131:Combined Modality Therapy / Q000379:methods; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000532:radiotherapy; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000517:prevention & control
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D066246:ErbB Receptors